Latest studies
Every paper our editors flag with a plain-language note and an evidence rating. Filter by evidence, species, or design to find what actually applies to you.
- Study · KisspeptinWeak / none
The kisspeptin analog C6 elicits greater tachyphylaxis and transcriptional activation than kisspeptin-10 and -54.
This in vitro pharmacology directly compares kisspeptin-10 and kisspeptin-54 against a synthetic analog, relevant background for how different kisspeptin forms behave at the receptor. Findings are cell-based only and focused on drug-discovery characterization, including the tachyphylaxis (desensitization) seen with continuous stimulation. Useful context rather than a human protocol signal.
Molecular and cellular endocrinologyn=—In vitroOct 1, 2026 - Study · KisspeptinWeak / none
Kisspeptin-54 confers renal protection in diabetic nephropathy by ameliorating endothelial permeability through ZEB1 inhibition.
This is a preclinical study in which kisspeptin-54 was directly administered to diabetic mice and applied to cultured kidney endothelial cells, with reported effects on barrier function and markers of renal injury. As mechanistic animal and in-vitro work, the evidence is early-stage and not yet tested in humans. It is a genuine kisspeptin intervention study, so it is relevant, though findings should be read as preliminary.
Tissue & celln=—AnimalAug 1, 2026 - Study · KisspeptinWeak / none
Exogenous Kisspeptin-10 inhibits ovarian cancer progression through targeting the SP1-hTERT-ZEB1 regulatory axis.
This in vitro study applies exogenous kisspeptin-10 to ovarian cancer cell lines and reports anti-metastatic signaling effects. It is cell-culture only, so it is an early mechanistic observation rather than evidence in animals or humans. A genuine kisspeptin-as-agent study but at the weakest tier of evidence.
Cytotechnologyn=—In vitroAug 1, 2026 - Study · KisspeptinWeak / none
Kisspeptin.
A brief overview article centered on kisspeptin, a tracked peptide involved in reproductive hormone regulation. No abstract detail is available, so scope and depth are unclear, but the topical focus is directly on the peptide. Likely background reference material.
Trends in endocrinology and metabolism: TEMn=——Jul 15, 2026 - Study · KisspeptinWeak / none
Kisspeptin-54 attenuates acute lung injury in septic mice through AMPK-mediated suppression of NLRP3 inflammasome.
A mouse study reporting that exogenous kisspeptin-54 was associated with improved survival and reduced sepsis-induced lung injury via AMPK-mediated suppression of the NLRP3 inflammasome. Findings are preclinical and in a non-reproductive context, so they should not be extrapolated to humans. Directly administers a tracked peptide.
Neuropeptidesn=—AnimalJun 23, 2026 - Study · KisspeptinWeak / none
Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices.
This study is not a clinical or pharmacological investigation — it is a doping-control analytical methods paper, and should be read as such. Researchers developed and validated a streamlined workflow capable of detecting 54 prohibited substances, including BPC-157 and TB-500, across dried blood spots, serum, and plasma using a single microextraction step followed by liquid chromatography coupled with high-resolution mass spectrometry. The analytical performance was satisfactory by laboratory standards: detection limits ranged from 0.05–1.25 ng/mL, no carry-over was observed, and matrix effects were modest (5–33%). Notably, dried blood spot matrices preserved all compounds for the full study duration under non-refrigerated conditions — a meaningful practical advantage for anti-doping sample logistics. For readers tracking BPC-157 and TB-500 specifically: the stability data are striking. Both peptides showed complete degradation in serum within one week at room temperature or refrigerator temperature — a finding with direct implications for detection windows in anti-doping contexts. Dried matrices retained detectability throughout. This paper contributes nothing to the...
The Analystn=——Jun 22, 2026 - Study · KisspeptinWeak / none
Dynamic modulation of LH secretion by continuous kisspeptin infusion in healthy men.
This is a direct human study administering kisspeptin-10 by continuous infusion and tracking reproductive hormone responses. The sample is only three men and the design is exploratory physiology, so it is a preliminary signal rather than a controlled trial. Genuinely on-topic for how kisspeptin acts in humans, including the partial desensitization observed over 24 hours.
Hormones (Athens, Greece)n=——Jun 2, 2026 - Study · KisspeptinWeak / none
Kisspeptin-10 regulates glycosaminoglycan and decorin content in human cardiac fibroblast cultures.
A cell-culture study, not a human or animal trial, so findings speak only to mechanism. Kisspeptin-10 was the direct subject and showed a dose-dependent, receptor-dependent signal associated with cardiac extracellular-matrix remodeling that would need in vivo confirmation.
Pharmacological reportsn=—In vitroMay 20, 2026